Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 570.

https://doi.org/10.1182/blood-2019-128178

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Max Topp, MD, Tom Van Meerten, MD PhD, Roch Houot, MD PhD, Monique C. Minnema, Noel Milpied, MD, Pieternella J. Lugtenburg, MD PhD, Catherine Thieblemont, MD PhD, Martin Wermke, MD, Kevin Song, MD, Irit Avivi, MD, John Kuruvilla, MD, Ulrich Dührsen, Prof, MD PhD, Rachel Chu, PhD, Lianqing Zheng, PhD, Vicki Plaks, PhD, Anne Kerber, MD, Marie Jose' Kersten, MD PhD

Blood (2019) 134 (Supplement_1): 243.

https://doi.org/10.1182/blood-2019-126081

Published: 2019

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Non-Transferrin-Bound Iron Serves As Iron Source for Aspergillus Fumigatus Growth

Verena Petzer, MD, Piotr Tymoszuk, PhD, Markus Seifert, Dorothea Orth-Höller, MD, Martin Wermke, MD, Uwe Platzbecker, MD, Günter Weiss, MD, Hubertus Haas, PhD, Igor Theurl, MD PhD

Blood (2017) 130 (Supplement 1): 2214.

https://doi.org/10.1182/blood.V130.Suppl_1.2214.2214

Published: 2017

Journal Articles

External Validation of the Revised PAM Score for Patients with AML Scheduled for Allogeneic Hematopoietic Stem Cell Transplantation

Frederike Kollinger, Jan Moritz Middeke, MD, Maria Hardtmann, Christian Klesse, Friedrich Stölzel, MD, Martin Wermke, MD, Malte von Bonin, MD, Katja Sockel, MD, Cornelia S Link, MD, Christoph Röllig, MD, Christian Thiede, MD, Uwe Platzbecker, MD, Gerhard Ehninger, MD, Martin Bornhäuser, MD, Johannes Schetelig, MD MSc

Blood (2016) 128 (22): 3495.

https://doi.org/10.1182/blood.V128.22.3495.3495

Published: 2016

Journal Articles

The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial

Martin Wermke, MD, Julia Eckoldt, Katharina Goetze, MD, Stefan A. Klein, Gesine Bug, MD, Friedrich Stölzel, MD, Malte von Bonin, MD, Johannes Schetelig, MD M. Sc,, Michael Laniado, MD, Verena Plodeck, MD, Wolf-Karsten Hofmann, MD, Gerhard Ehninger, MD, Martin Bornhäuser, MD, Dominik Wolf, MD, Igor Theurl, MDPhD, Uwe Platzbecker, MD

Blood (2015) 126 (23): 386.

https://doi.org/10.1182/blood.V126.23.386.386

Published: 2015

Journal Articles

Selective Expansion of Regulatory T-Cells during Lenalidomid Treatment of MDS with Isolated Deletion 5q

Martin Wermke, MD, Claudia Schuster, Claudia Schönefeldt, Sebastian Tuve, MD, Gerhard Ehninger, MD, Detlef Haase, Ulrich Germing, MD, Martin Bornhäuser, MD, Uta Oelschlaegel, PhD, Malte von Bonin, MD, Uwe Platzbecker, MD

Blood (2014) 124 (21): 4654.

https://doi.org/10.1182/blood.V124.21.4654.4654

Published: 2014

Journal Articles

Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag

Uwe Platzbecker, MD, PhD, Katja Sockel, MD, Claudia Schönefeldt, Daniel Nowak, MD, Susann Helas, PhD, Christoph Röllig, MD, Maximilian Mossner, Johann-Christoph Jann, Gerhard Ehninger, MD, Wolf-Karsten Hofmann, MD, Martin Bornhäuser, MD, Christian Thiede, MD, Martin Wermke, MD

Blood (2013) 122 (21): 4923.

https://doi.org/10.1182/blood.V122.21.4923.4923

Published: 2013

Journal Articles

Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease -

Felix von Dalowski, Michael Kramer, PhD, Martin Wermke, MD, Christoph Röllig, MD, Nael Alakel, MD, Friedrich Stölzel, MD, Stefani Parmentier, MD, Katja Sockel, MD, Mathias Krech, PhD, Marc Schmitz, MD, Uwe Platzbecker, MD, PhD, Johannes Schetelig, MD, M. Sc, Martin Bornhauser, MD, Malte von Bonin, MD

Blood (2013) 122 (21): 4612.

https://doi.org/10.1182/blood.V122.21.4612.4612

Published: 2013

Journal Articles

Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG

Martin Wermke, MD, Claudia Schuster, Claudia Schönefeldt, Christiane Jakob, MD, Malte von Bonin, MD, Florian Nolte, MD, Philipp Kiewe, MD, Regina Herbst, MD, Ulrich Germing, MD, Michael Aigner, PhD, Detlef Haase, MD, Ina-Maria Klut, PhD, Nadja Jaekel, Gustavo Baretton, MD, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Wolf-Karsten Hofmann, MD, Uwe Platzbecker, MD, PhD

Blood (2013) 122 (21): 2808.

https://doi.org/10.1182/blood.V122.21.2808.2808

Published: 2013

Journal Articles

A Genome Wide shRNA Screen In Primary Human AML Cells Identifies ROCK1 As a Novel Therapeutic Target

Martin Wermke, MD, Aylin Camgoz, Maciej Paszkowski-Rogacz, PhD, Sebastian Thieme, PhD, Malte von Bonin, MD, Andreas Dahl, PhD, Mirko Theis, PhD, Gerhard Ehninger, MD, Sebastian Brenner, MD, Martin Bornhäuser, MD, Frank Buchholz, PhD

Blood (2013) 122 (21): 170.

https://doi.org/10.1182/blood.V122.21.170.170

Published: 2013

Journal Articles

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

Friedrich Stölzel, MD, Michael Kramer, Brigitte Mohr, PhD, Martin Wermke, MD, Martin Bornhäuser, MD, Gerhard Ehninger, Markus Schaich, MD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 1715.

https://doi.org/10.1182/blood.V120.21.1715.1715

Published: 2012

Journal Articles

The Immunologic Composition of the Bone Marrow Changes Rapidly During the Harvest Procedure

Martin Wermke, MD, Cathrin Wegner, Malte von Bonin, MD, Sebastian Tuve, MD, Claudia Schönefeldt, MSc, Kristina Hölig, MD, Uta Oelschlegel, PhD, Martin Bornhaeuser, MD, Uwe Platzbecker, MD, Rainer Ordemann, MD

Blood (2012) 120 (21): 1915.

https://doi.org/10.1182/blood.V120.21.1915.1915

Published: 2012

Journal Articles

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Sebastian Tuve, MD, Felix Bahr, Rebekka Wehner, PhD, Uwe Platzbecker, MD, Martin Wermke, MD, Nona Shayegi, MD, Jan Moritz Middeke, MD, Christoph Röllig, Johannes Schetelig, Gerhard Ehninger, Marc Schmitz, MD, Martin Bornhäuser, MD

Blood (2012) 120 (21): 4167.

https://doi.org/10.1182/blood.V120.21.4167.4167

Published: 2012

Journal Articles

Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation

Katja Sockel, MD, Claudia Schönefeldt, MSc, Sieghart Sopper, Martin Wermke, MD, Marc Schmitz, MD, Gerhard Ehninger, Martin Bornhäuser, MD, Dominik Wolf, MD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 4122.

https://doi.org/10.1182/blood.V120.21.4122.4122

Published: 2012

Journal Articles

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Uwe Platzbecker, MD, Friederike Braulke, Andrea Kuendgen, Katharina S. Götze, Gesine Bug, Katayoon Shirneshan, Christoph Röllig, Martin Bornhäuser, MD, Ralph Naumann, MD, Jürgen Neesen, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, Gerhard Ehninger, Prof., Ulrich Germing, MD, Detlef Haase, Martin Wermke, MD

Blood (2012) 120 (21): 921.

https://doi.org/10.1182/blood.V120.21.921.921

Published: 2012

Journal Articles

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia

Marc Cartellieri, Irene Michalk, Malte von Bonin, Thomas Krüger, Slava Stamova, Stefanie Koristka, Claudia Arndt, Anja Feldmann, Marc Schmitz, Martin Wermke, MD, Dirk Lindemann, Martin Bornhäuser, Gerhard Ehninger, MD, Michael Bachmann

Blood (2011) 118 (21): 2618.

https://doi.org/10.1182/blood.V118.21.2618.2618

Published: 2011

Journal Articles

Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients

Martin Wermke, MD, Anne Schmidt, Jan Moritz Middeke, Katja Sockel, MD, Malte von Bonin, MD, Verena Plodeck, Michael Laniado, MD, Johannes Schetelig, Gerhard Ehninger, MD, Martin Bornhauser, Uwe Platzbecker, MD

Blood (2011) 118 (21): 489.

https://doi.org/10.1182/blood.V118.21.489.489

Published: 2011

NARROW

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Non-Transferrin-Bound Iron Serves As Iron Source for Aspergillus Fumigatus Growth

External Validation of the Revised PAM Score for Patients with AML Scheduled for Allogeneic Hematopoietic Stem Cell Transplantation

The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial

Selective Expansion of Regulatory T-Cells during Lenalidomid Treatment of MDS with Isolated Deletion 5q

Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag

Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease -

Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG

A Genome Wide shRNA Screen In Primary Human AML Cells Identifies ROCK1 As a Novel Therapeutic Target

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

The Immunologic Composition of the Bone Marrow Changes Rapidly During the Harvest Procedure

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia

Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only